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Global	overview	and	highlights
N	>	115,000
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Prepared	by	the	GDS	Core	Research	Team
Dr	Adam	Winstock,	Dr	Monica	Barratt,	Dr	Jason	Ferris	&	Dr	Larissa	Maier
On	behalf	of	the	GDS	Core	Research	Team	and	everyone	of	our	amazing	international	network	partners	and	supportive	
media	organisations we’d	like	to	share	our	headline	report	deck.	I	know	it	won’t	have	everything	that	everyone	wants	
but	we	are	hopeful	it	will	give	people	an	idea	of	how	the	world	of	drugs	is	changing	and	highlight	some	of	the	key	
things	that	we	think	people	can	better	engage	with	to	keep	themselves	and	those	they	care	for	safe.	
Once	we	cleaned	the	data	from	150,000	people	we	chose	to	use	data	from	just	under	120,000	people	this	year	for	
these	reports.	We	have	data	reports	addressing	18	different	areas	for	over	25	countries.	We	can	only	share	a	fraction	
of	what	we	have	here	on	the	site.	However,	we	are	very	open	to	sharing	the	other	findings	we	have	and	would	ask	
researchers	and	public	health	groups	to	contact	us	so	we	can	discuss	funding	and	collaboration.	
We	have	almost	completed	designing	GDS2018	so	that	we	can	start	piloting	early	and	give	countries	where	we	have	
not	yet	found	friends	to	reach	out	to	us.	We	particularly	want	to	hear	from	people	in	Japan,	Eastern	Europe,	Africa	and	
the	Middle	East.
Dr	Adam	R	Winstock	Founder	and	CEO	Global	Drug	Survey
Consultant	Psychiatrist	and	Addiction	Medicine	Specialist
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Hi	everyone
We	hope	you	enjoy	this	report	
which	we	gladly	share	with	
you	with	for	free.	If	you	like	what	
Global	Drug	Survey	does
then	we’d	like	to	ask	
you	to	make	the	smallest	of	
donations	– the	price	of	joint,	a	pill,	a	line,	a	beer	(£10).	
Your	donation	will	help	us	carry	on	being	independent,	run	the	survey	and	encourage	
governments,	communities	and	people	to	have	honest	conversations	about	drugs.	
Thank	you	
Adam	on	behalf	of	GDS
We	think	this		will	be	interesting.	
This	report	is	embargoed	until	
Wednesday	May	24th	2017	
Using	and	reporting	the	data
In	all	copy	related	to	the	data	provided	the	study	should	be	referred	to	as	
Global	Drug	Survey	2017
For	further	information	and	requests	for	local	country	and	bespoke	data	
reports	please	contact	adam@globaldrugsurvey.com
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Global	Drug	Survey	
runs	the	world’s	largest	drug	survey
A	total	of	119,846	people	from	over	50	countries	
participated	in	GDS2017.	Of	these	115,523 had	their	data	
used	in	the	preparation	of	these	reports	.	
GDS	is	an	independent	global	drug	use	data	exchange	hub	
that	conducts	university	ethics	approved,	anonymous	on-
line	surveys.	We	collaborate	with	global	media	partners	
who	act	as	hubs	to	promote	our	work.	
GDS	is	comprised	of	experts	from	the	fields	of	medicine,	
toxicology,	public	health,	psychology,	chemistry,	public	
policy,	criminology,	sociology,	harm	reduction	and	
addiction.	We	research	key	issues	of	relevance	and	
importance	to	both	people	who	use	drugs	and	those	who	
craft	public	health	and	drug	policy
We	aim	to	make	drug	use	safer	regardless	of	the	legal	
status	by	sharing	information		in	a	credible	and	
meaningful	way.	
Our	last	4	surveys,	run	at	the	end	of	2013,	2014,	
2015,	and	2016	received	over	400,000	responses.
Over	the	last	decade	GDS	has	successfully	supported	
the	widespread	dissemination	of	essential	information	
both	to	people	who	use	drugs	through	our	media	
partners	and	to	the	medical	profession	through	
academic	papers,	presentation	at	international	
conferences,	expert	advisory	meetings	and	through	
www.drugsmeter.com and	www.drinksmeter.com
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Global	Drug	Survey	2017 Mission
To	ensure	our	findings	are	accessible	and	useful	to	
people	who	use	drugs	we	offer	a	range	of	free	
harm	reduction	resources	such	as	
• the	GDS	Highway	Code	
www.globaldrugsurvey.com/brand/the-highway-
code/
• the	Safer	Use	Limits	www.saferuselimits.co/
• digital	health	apps	to	deliver	brief	screening	and	
intervention:	www.drinksmeter.com
• harm	reduction	and	drug	education	videos	
available	on	our	YouTube	channel	
www.youtube.com/user/GlobalDrugSurvey When	reporting	the	results	in	print,	online	
and	on	TV	we	ask	all	our	media	partners	to	
place	links	to	these	free	resources	where	
suitable.
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Resources
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Country	breakdown	of	respondents	by	country	(to	the	nearest	50)
Country	 n Country	 n
Germany 36000 Greece 1600
Denmark 13500 Mexico 1350
USA 10100 Colombia 1050
Switzerland 7850 Portugal 900
UK 5900 Belgium 800
Australia 5750 Norway 550
Canada 5400 France 500
Austria 4850 Spain 500
New	Zealand 3800 Sweden 500
Italy 3500 Ireland 500
Netherlands 3250 Poland 450
Brazil 3000 Finland 400
Hungary 2850 Iceland/Croatia/Argentina 250
GDS	is	comprised	of	the	Core	Research	Team	and	an	
international	partnership	with	researchers	and	harm	
reduction	organisations in	over	20	countries.	Since	
2013	we	have	published	over	25	papers	with	another	
12	in	press.
Recent	work	by	GDS	suggests	that	the	age	and	sex	
distribution	of	those	who	volunteer	to	be	surveyed	is	
not	vastly	different	between	these	non-probability	
and	probability	methods.	We	conclude	that	opt-in	
web	surveys	of	hard-to-reach	populations	are	an	
efficient	way	of	gaining	in-depth	understandings	of	
stigmatized	behaviours	among	hidden	populations,	
and	are	appropriate,	as	long	as	they	are	not	used	to	
estimate	drug	use	prevalence	of	the	general	
population	(Barratt	et	al	in	press).		
Labhart F,	Ferris	J, Winstock A,	Kuntsche E.	The	country	level	
effects	of	drinking,	heavy	drinking	and	drink	prices	on	pre-
drinking:	An	international	comparison	of	25	countries.	Drug	
Alcohol	Rev.	2017.
Barratt,	M.J.,	Ferris,	J.A.,	Winstock,	A.R.	Safer	scoring?	
Cryptomarkets,	social	supply	and	drug	market	violence.	IJDP	
2016.
Freeman	TP,	Winstock AR.	Examining	the	profile	of	high-
potency	cannabis	and	its	association	with	severity	of	cannabis	
dependence.	Psychol Med.	2015;45(15):3181–9.
Winstock A,	Lynskey M,	Borschmann R,	Waldron	J.	Risk	of	
emergency	medical	treatment	following	consumption	of	
cannabis	or	synthetic	cannabinoids	in	a	large	global	sample.	J	
Psychopharmacol.	2015;29(6):698–703.	
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GDS	methods	&	academic	credentials Recent	publications
Probability	based	surveys	tell	you	about	the	size	of	
the	drug	use	problem	in	your	country;	GDS	tells	you	
what	to	do	about	it.
– Dr	Adam	Winstock
More	information	on	our	methods		
Our	recruitment	strategy	is	an	example	of	non-purposive	
sampling.	We	acknowledge	that	this	has	significant	limitations,	
most	notably	with	respect	to	response	bias.	It	is	more	likely	
that	individuals	will	respond	to	surveys	if	they	see	topics	or	
items	that	are	of	interest	to	them,	and	thus	by	definition	will	
differ	from	those	who	do	not	participate.	
Don’t	look	to	GDS	for	national	estimates.	GDS	is	designed	to	
answer	comparison	questions	that	are	not	dependent	on	
probability	samples.	The	GDS	sample	is	thus	most	effectively	
used	to	compare	population	segments,	young,	old,	males,	
females,	gay,	straight,	clubbers,	thin	people,	obese	people,	
vegetarians,	those	with	a	current	psychiatric	diagnosis,	
students,	northerners,	southerners	etc. Given that	GDS	recruits	
younger,	more	involved	drug	using	populations	we	are	able	to	
spot	emerging	drug	trends	before	they	enter	into	the	general	
population.	GDS	complements	existing	drug	use	information	
and	provides	essential,	current	data	on	the	patterns	of	use,	
harms,	health	and	well-being	experienced	by	the	drug	users	in	
your	country.
The	founder	and	CEO	of	GDS	is	Dr Adam	R	Winstock MD
Adam	is	a	Consultant	Addiction	Psychiatrist	and	academic	
researcher	based	in	London.	The	views	presented	here	are	
entirely	his	own	and	have	no	relationship	to	those	of	his	
current	employers	or	affiliate	academic	organizations.	No	
government,	regulatory	authority,	corporate	organization	or	
advocacy	group	has	influenced	the	design	of	the	survey	or	
content	of	report.
Limitations
This	is	not	a	nationally	representative	sample,	but	it	does	represent	one	
of	the	largest	studies	of	drug	use	ever	conducted	in	Switzerland.	
Although	the	findings	cannot	be	said	to	be	representative	of	the	wider	
Swiss	population,	they	do	provide	a	useful	snapshot	of	what	drugs	are	
being	used	and	how	they	are	impacting	upon	people’s	lives	in	
Switzerland.	The	findings	can	inform	policy,	health	service	development	
and	most	importantly		provide	people	who	drink	and/or	take	drugs	with	
practical	advise	on	how	to	keep	healthy	and	minimize	the	harms	
associated	with	the	use	of	substances.	
In	the	time	frame	and	resources	provided	only	these	preliminary	
analyses	are	provided	and	given	enormous	data	we	gathered,	
composite	results	on	key	issues	are	provided	only.	Stories	are	thus	
based	on	preliminary	findings	and	are	subject	to	change	on	further	
analyses.	Results	have	usually	provided	to	the	nearest	full	or	half	
percent.
Limitations	with	cross-country	comparison
Throughout	this	report	we	provide	some	comparisons	on	some	key	
areas	that	may	be	of	interest	to	readers	of	your	publications.	Because	
the	samples	we	have	obtained	from	different	countries	vary	
considerably	in	the	size,	its	representativeness,	the	precise	
demographics	and	other	characteristics	of	respondents	such	as	age,	
gender,	involvement	in	clubbing	and	drug	use,	these	comparisons	have	
to	be	treated	with	some	caution.	
The	results	do	not	necessary	represent	the	wider	drug	using	
community.	Saying	that	if	you	ask	a	100	people	in	a	country	how	much	a	
drug	costs	or	a	group	of	25,000	MDMA	users	how	often	they	need	to	
seek	emergency	medical	help	you	can’t	dismiss	the	findings	as	
irrelevant	and	inconsistent	with	more	representative	samples.	For	
countries	with	small	numbers	the	findings	need	to	be	treated	with	even	
more	caution.	
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Over	the	last	4	years	>	400,000	people	have	
taken	part	in	our	surveys.	
GDS2018 launches	in		October	2017.
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• Don’t	look	to	GDS	for	national	
estimates.	GDS	is	designed	to	answer	
comparison	questions	that	are	not	
dependent	on	probability	samples.	
• GDS	database	is	huge	but	its	non-
probability	sample	means	analyses	
are	suited	to	highlight	differences	
among	user	populations.
• GDS	recruits	younger,	more	involved	
drug	using	populations.	We	spot	
emerging	drugs	trends	before	they	
enter	into	the	general	population	
• GDS	is	an	efficient	approach	to	gain	
content	rich	data	that	explores	diverse	
health	outcomes	associated	with	the	
use	of	drugs	and	alcohol	across	the	
population	of	your	country.	
• GDS	helps	you	better	understand	the	
quantitative	dynamics	of	personal	
decision-making	about	drug	use,	
detects	regional	differences	in	
patterns	of	drug	use	and	related	harm,	
and	informs	novel	interventions.
• Provides	current	data	on	the	patterns	
of	use,	harms,	health	and	well-being	
experienced	by	the	full	spectrum	of	
users
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What	GDS	won’t	do	for	you What	GDS	will	do	for	you
þ Age:	mean	age	and	%	in	different	age	band	categories
þ Gender:	male	vs.	female	(1%	who	indicated	they	were	transgender	were	removed	for	these	analyses)
þ Sexual	orientation
þ Ethnicity
þ Educational	attainment
þ Employment/	studying
þWho	they	live	with
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Key	findings	– Demographics
Global	sample
The	GDS2017	reports	are	based	on	115,523	participants.
Of	these,	78,592	were	male	(68%)	and	36,931	were	female	(32%).
The	mean	age	was	29.1	years,	with	46.7%	under	25	years	&	24.3%	over	35	years.
Ethnicity
White 90.5%
Mixed 3.2%
Asian	(Pakistani,	Indian,	Bangladeshi) 0.4%
Black	African/Black	Caribbean 0.3%
Hispanic	Latino 2.8%
SE	Asian 0.4%
Other 1.8%
Aboriginal 0.2%
Native	American 0.2%
Black	American 0.2%
Global Drug Survey GDS2017 © Not to be reproduced without authors permission
Demographics	– global	participants
32.0% 68.0%
Female:	36,931 Male:	78,592
Mean	age 29.1
<25	years 46.7%
25-34	years 29.0%
35+	years 24.3%
Employment	status
Paid	Employment 64.8%
Unemployed	(looking	for	work)	 6.1%
Unemployed	(not	looking	for	work)	 29.2%
Students
Yes	full	time 29.5%
Yes,	part	time 8.9%
No 61.6%
Education	
41.8%	have	a	university	degree	or	higher
Clubbing
47.6%*	of	respondents	go	clubbing	at	least	every	3	months	
*question	only	answered by	n=59,607
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DRUG	USE	AMONG	THE	SAMPLE
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Drug	use	among	the	GDS2017	sample
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Global	comparison of emergency medical treatment seeking – GDS2017	all	substances
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Alcohol	– Global	
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
GDS2017	has	continued	to	map	global	drinking	patterns	using	the	Alcohol	Use	Disorders	Identification	Test	(AUDIT)	a	
World	Health	Organisation	questionnaire	to	ascertain	harmful	drinking	levels	and	dependence.	This	includes	how	often	
individuals	drank	alcohol	and	how	many	drinks	they	would	have	on	a	typical	day	of	use. The	WHO	2006	document	by	
Babor et	al.	lists	4	sets	of	summary	scores	0-7,8-15,16-19,20	and	above.	
Total	scores	of	8	or	more	are	recommended	as	indicators	of	hazardous	and	harmful	alcohol	use	and	dependence.	
Higher	scores	simply	indicate	greater	likelihood	of	hazardous	and	harmful	drinking.	However,	such	scores	may	also	
reflect	greater	severity	of	alcohol	problems	and	dependence,	as	well	as	a	greater	need	for	more	intensive	treatment.	
AUDIT	scores	in	the	range	of	8-15	represented	a	medium	level	of	alcohol	problems	whereas	scores	of	16	and	above	
represented	a	high	level	of	alcohol	problems.	AUDIT	scores	of	20	or	above	warrant	further	diagnostic	evaluation	for	
alcohol	dependence.
Following	up	on	a	consistent	GDS	finding	that	over	1	in	3	respondents	to	GDS	express	a	desire	to	drink	less	in	the	
following	12		months,	this	year	we	have	focused	on	how	these	motivated	people	would	like	to	obtain	help	to	reduce	
their	drinking	.	With	the	growth	of	digital	health	applications	to	raise	awareness	among	the	general	population	of	the	
health	harms	associated	with	excessive	drinking,	including	GDS’s	own	highly	successful	free	online	app	Drinks	Meter	
we	wanted	to	see	how	attractive	different	approaches	were	within	different	populations.	We	also	report	about	last	
year	drinkers	who	report	seeking	emergency	medical	treatment	in	the	previous	12	months.
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Background
Drinking	harms	and	adverse	experiences	
þ The	%	in	each	AUDIT	score	category	for	each	country	as	a	whole	and	by	gender	and	age	(16-24	and	25+	years	old)
þ The	%	of	all	drinking	respondents	in	each	country	and	by	gender	and	age	(16-24	and	25+	years	old)
þ The	%	who	reported	feels	of	regret	or	guilt	at	least	monthly	because	of	their	drinking	
þ The	%	who	reported	being	unable	to	remember	what	appended	the	night	before	because	of	their	drinking
þ The	%	who	reported	having	sought	emergency	medical	treatment	in	the	last	12	months	as	a	result	of	drinking	alcohol
Who	wants	to	drink	less,	who	wants	help	and	what	form	would	that	help	take?
þ The	%	of	last	year	drinkers	who	would	like	to	drink	less	in	the	next	12	months
þ The	%	of	last	year	drinkers	who	would	like	help	to	reduce	drinking
þ Which	approach	would	be	most	likely	used	if	help	is	sought	by	gender	and	age	(16-24	and	25+	years	old)
þ The	%	of	last	year	drinkers	who	report	that	they	actually	plan	to	seek	support	to	cut	down/	stop	drinking	in	the	next	12	months
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Selected	data	presented	here	comes	from	the	section	that	includes
A	total	of	114,039 drinkers	participated	in	GDS2017	and	were	used	in	the	preparation	of	the	this	report.
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AUDIT	Scores	
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Alcohol	users	that	aim	to	drink	less	next	year	&	help	seeking	behavior
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What	sort	of	help	would	people	choose	to	seek	help	to	reduce/	stop	use?
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Counselling	via	
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Please	refer	your	readers	to	our	free,	anonymous	and	confidential	on-line	tool	
(www.drinksmeter.com) and	app	(the	Drinks	Meter),	recently	rated	as	the	most	highly	
praised	digital	app	(Milward et	al	2016)	to	help	people	with	drinking	with	over	90%	
recommending	it	to	their	friends	(Garnett	et	al	2017)	and	over	60%	saying	they	plan	to	
drink	less	after	completing	it.	It	takes	8-10	minutes	to	do	and	it	can	change	a	person’s	life.	
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Drinks	Meter
Contact	us	if	you	want	to	translate	it	into	your	language	– we	can	create	bespoke	
regional	content	and	use	local	guidelines
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Cannabis	– Global	based	on	n	>	69,000	last	year	users	
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
Cannabis	remains	the	world’s	most	widely	used	‘illicit’	drug.	Regulatory	change	in	many	countries	
and	the	development		of	new	technologies	to	deliver	cannabis	in	less	harmful	ways	are	an	
important	accompaniment	to		this	change	and	pave	the	way	for	new	public	health	approaches	to	
reducing	the	public	health	harms	associated	with	its	use.	This	year	in	our	main	cannabis	section	
we	focus	on	national	patterns	of	use	and	purchase	and	how	price,	dominant	preparations	and	
methods	of	use	vary	across	cultures.	
GDS2017	was	interested	in	what	sorts	of	people	are	most	likely	willing	to	use	less	cannabis	and	
how	they	might	seek	help	to	reduce	or	stop	their	use.	This	is	important	since	it	is	possible	that	
changing	the	legal	status	of	cannabis	may	make	people	feel	more	comfortable	about	seeking	
help.
In	our	specialist	sections	we	look	at	the	medical	use	of	cannabis	and	offer	a	global	perspective	on	
how	cannabis	users	would	like	to	see	cannabis	legally	regulated.	If	you	would	like	to	help	fund	our	
medical	cannabis	data	please	contact	us.
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Background
Cannabis	use	patterns	and	adverse	experiences	
þ Mean	number	of	cannabis	use	days	in	the	last	year	by	gender	
þ The	%	who	had	used	1,	2-10,	11-50,	51-100,	101-200,	201-300	and	>	300	x	in	the	last	year	
þ What	types	of	cannabis	are	used	most	commonly	by	country
þ How	much	cannabis	is	used	per	day
þ How	many	joints	users	get	from	one	gram	of	cannabis	
þ The	most	common	methods	of	use	by	country	including	what	percentage	of	users	mix	cannabis	with	tobacco
þ The	occasion	for	the	first	and	last	joint	of	the	day
þ How	many	hours	per	day	cannabis	users	are	stoned	for
þ Information	on	where	users	get	their	cannabis	from	and	if	they	pay	how	much	they	usually	pay	for	one	gram
þ Motives	for	use	– recreational	vs.	medical
þ The	%	of	users	who	would	like	to	use	less	cannabis	and	preferred	styles	of	help	seeking
þ The	%	who	reported	having	sought	emergency	medical	treatment	in	the	last	12	months	as	a	result	of	cannabis	use
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Selected	data	presented	here	comes	from	the	section	that	includes
A	total	of	69,299 cannabis	users	participated	in	GDS2017	and	were	used	in	the	preparation	of	the	this	report.
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Compared	to	the	entire	GLOBAL GDS2017	cannabis	using	sample	
All	vs.	Males	vs.	Females	
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Mean	number	of	days	=	135.4 Mean	number	of	days	=	144.5 Mean	number	of	days	=	110.2
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Global	comparison	– Who	smokes	a	joint	within	5	min/	1	hour	(combined)	of	waking?
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(Main)	Method	of	cannabis	use	 Types	of	cannabis	used
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Global	comparison – who uses tobacco with their cannabis
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How	many	joints	from	a	gram*		(+/-tobacco)
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A	mean	of	4.3	joints	/gram	when	rolled	
with	tobacco	v	2.7	when	rolled	without	
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Cannabis	users	who	aim	to	use	less	cannabis	next	year	&	help	seeking	behavior
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Seeking	emergency	medical	treatment	following	the	use	of	cannabis	last	year	(%)
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Seeking	emergency	medical	treatment	following	the	use	of	cannabis	4	year	global	trends
(global	n	>	200,000)
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We	hope	you	are	enjoying	this	report	
which	we	gladly	share	with	
you	with	for	free.	If	you	like	what	
Global	Drug	Survey	does
then	we’d	like	to	ask	
you	to	make	the	smallest	of	
donations	– the	price	of	joint,	a	pill,	a	line,	a	beer.	
Your	donation	will	help	us	carry	on	being	independent,	run	the	survey	and	
encourage	governments,	communities	and	people	to	have	honest	
conversations	about	drugs.	
Finding	this	interesting?	
Cannabis	regulation	– global	
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For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
• This	year,	our	main	cannabis	section	has	focused	on	patterns	of	use	and	purchase	and	how	price,	
dominant	preparations	and	methods	of	use	vary	across	countries.	
• In	our	specialist	section	on	cannabis	regulation,	we	offer	a	global	perspective	on	how	cannabis	users	
would	like	to	see	cannabis	legally	regulated.	
• This	analysis	is	based	on	>	8500 respondents to	GDS2017	– all	of	whom	reported	that	they	had	ever	used	
cannabis	and	completed	the	specialist	section	on	cannabis	regulation.	
• Respondents	were	73.2%	male	and	26.8%	female	and	on	average	29.2	years	old
à 42.7%	<	25,	32.5%	25-34,	and	25.2%	35+	years
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Background
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þ How	cannabis	users	perceive	current	regulations	in	their	region
þ How	cannabis	users	would	like	to	see	the	use	of	non-medical	cannabis	regulated
þ How	views	on	preferred	approaches	vary	across	countries
Cannabis	users’	views	on
þ How	much	legal	available	cannabis	should	cost	when	compared	to	the	current	price
þ Percentage	of	cannabis	tax	revenue	that	should	go	to	treatment	and	harm	reduction
þ Level	of	support	for	a	minimum	pricing	or	lower	prices	for	low	THC	products
þ Types	of	cannabis	products	that	should	be	available	on	a	regulated	market	
þ Preferred	market	restrictions	e.g.	on	sales	to	minors,	to	mentally	ill,	need	for	labelling
þ Who	should	grow	and	sell	cannabis	in	a	legal	market	e.g.	government	or	private	companies
þ What	they	see	as	potential	causes	of	concern	from	cannabis	legalization
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Selected	data	presented	here	comes	from	the	section	that	includes
A	total	of	8,500	recent	cannabis	users	were	included	in	the	preparation	of	this	section	of	the	report.
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Who	should	be	in	control	of	cannabis	sales	and	do	we	need	guidelines?
17% 
45% 
38% 
% 
Government
Private	companies
Not-for-profit	orgs
If	there	was	to	be	a	regulated	cannabis	market	in	your	country	who	
would	you	want	to	sell	the	cannabis?
Do	you	think	the	governments	should	
produce	cannabis	regulation	
guidelines	like	they	do	for	alcohol?
Yes		75.6%
No			10.2%
Unsure			14.2%	
Winstock	A	2014
www.saferuselimits.co
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Synthetic	cannabinoids	(SCRAs)	– Global
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For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
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Background
Over	the	last	5	years,	GDS	has	conducted	the	largest	on	the	use	
of	synthetic	cannabis	products	and	published	highly	cited	
papers.
• 1)	Winstock	et	al.	(2015).	Risk	of	seeking	emermedical
treatment	following	consumption	of	cannabis	or	synthetic	
gency cannabinoids	in	a	large	global	sample.	J	
Psychopharmacology	This	highlighted	that	the	risk	of	seeking	
emergency	medical	treatment	was	30	times	higher	in	users	
of	SCs	than	high	potency	cannabis.	
• 2)	Winstock	et	al.	(2013).	A	comparison	of	patterns	of	use	
and	effect	profile	with	natural	cannabis	in	a	large	global	
sample.	Drug	and	Alcohol	Dependence.	This	highlighted	that	
93%	of	users	preferred	natural	cannabis	and	that	SCs	had	a	
much	less	pleasant	effect	profile	than	natural	cannabis.
• 3)	Winstock	et	al.	(2013).	The	12-month	prevalence	and	
nature	of	adverse	experiences	resulting	in	emergency	
medical	presentations	associated	with	the	use	of	synthetic	
cannabinoid	products.	Human	Psychopharmacology:	Clinical	
and	Experimental.	This	highlighted	that	almost	1	in	40	last	
years	users	had	sought	emergency	medical	treatment	in	the	
previous	12	months.
Last	year	for	the	fouth year	running	we	identified	that	the	risk	of	seeking	
Emergency	Medical	Treatment	was	higher	following	the	use	of	synthetic	
cannabinoid	products	than	any	drug	we	looked	at	with	over	1	in	30	users	
seeking	EMT	in	the	last	year	with	that	figure	rising	to	1	in	8	of	those	using	
more	than	50	times.	Men	were	more	at	risk	than	women	with	4.2%	of	last	
year	users	reporting	seeking	EMT.	Figures	from	GDS2017	are	almost	
identical,	with	men	over	the	age	of	25	y	old	being	most	at	risk.	Once	again	
our	data	shows	that	these	are	a	diverse	group	of	drugs	with	the	risks	of	
seeking	EMT	varying	widely	between	countries	– with	the	UK	having	the	
highest	rates	with	over	one	in	10	users	seeking	EMT	in	the	last	year.
This	year	again	we	have	shown	that	over	65%	of	those	who	have	used	
SCRAs	on	at	least	50	days	in	the	last	year	have	experienced	3	or	more	
withdrawal	symptoms.	Stopping	in	not	easy	and	is	not	without	problems	
for	users.
Despite	international	regulation	that	has	tried	to	ban	many	of	these	
compounds	– the	profit	(10,000	%	+)	that	can	be	made	form	their	retail	
and	distribution	rivals	that	of	cocaine	but	with	a	fraction	of	the	risk	of	
interference	from	law	enforcement	agencies.	This	year,	we	continue	to	
track	the	evolution	of	these	diverse	drugs,	that	although	uncommon	in	
the	GDS	population	continue	to	to	be	popular	among	those	already	most	
disadvantaged	in	society	– the	homeless,	the	imprisoned	and	the	uncared	
for.
þ The	%	of	SCRA	use	by	country	
þ The	different	preparations	of	SCRAs	
þ The	common	methods	of	use	of	SCRAs	
þ For	those	rolling	joints	– mean	number	of	joints/	gram	(and	%	getting	10	or	more	from	one	gram)
þ The	%	obtaining	SCRAs	from	different	sources	
þ The	%	of	last	year	SCRA	users	who	had	used	50	or	more	times	in	the	past	year	and	the	%	of	these	who	
had	tried	to	stop	use
þ The	%	of	those	who	had	tried	to	stop	who	reported	different	withdrawal	symptoms	
þ The	%	of	last	year	users	of	SCRAs	who		sought	EMT	by	gender	and	age	(16-24	and	25+	years	old)
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Selected	data	presented	here	comes	from	the	section	that	includes
A	total	of	1,240	last	year	SCRA	users	participated	in	GDS2017	and	were	used	in	the	
preparation	of	the	this	section	of	the	GDS2017	report
Preparations	tried,	common	methods	of	use	and	joints/gram	in	the	last	12m		
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The	majority	of	respondents	sourced	synthetic	cannabis	from	
friends,	though	in	a	shift	from	previous	years	the	next	most	
common	source	are	dealers	(this	shows	country	variation)
In	person	at	a	shop	over	the	counter								 14.4%
In	person	at	a	shop	under	the	counter				 3.8%
Online	open	web																																								 15.6%
Online	darknet 1.9%
Dealer																																																														 17.3%
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Average	number	of	joints/	gram	was	7	(about	twice	as	
many	as	the	average	person	gets	from	a	gram	of	
natural	cannabis)
30	%	of	people	get	10	or	more	joints/	gram
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Vaping	– Global
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For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
The	rise	in	vape	technology	is	not	the	first	time	that	scientific	innovation	has	changed	the	way	we	use	
drugs.	The	invention	of	the	hypodermic	needle	allowed	purified	morphine	and	cocaine	extracted	from	their	
natural	origins	(the	opium	poppy	and	coca	leaf	respectively)	to	be	delivered	with	previously	unimaginable	
efficiency	and	dosing	accuracy.	
While	the	drive	behind	vaping	has	been	in	part	public	heath	(the	driver	behind	e-cigarettes)	and	medicinal	
(offering	medical	cannabis	users	a	way	of	using	cannabis	concentrates	such	as	Butane	Hash	Oil	without	
having	to	smoke	weed	is	great),	there's	no	doubt	that	vaping	cannabis	concentrates	offer	cannabis	users	
another	way	of	getting	high.	It	also	offers	huge	business	opportunities	for	new	vape	tech	companies.
This	year	we	moved	away	from	what	we	know	to	explore	the	relatively	new	phenomena	of	vaping	drugs	
other	than	cannabis	or	nicotine.	Yep	you	can	vape	other	drugs	and	you	don't	need	fancy	tech	either.	Many	
heroin	users	already	vape	- (though	we	incorrectly	term	it	smoking)	when	they	heat	heroin	on	a	foil	and	
inhale	the	vapourised fumes.	This	year	we	find	out	what	other	drugs	people	are	vaping	and	what	devices	
are	being	used.	
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Background
GDS2017	collected	a	huge	amount	of	data	on	vaping	this	year.	We	looked	at	what	drugs	were	vaped,	the	type	of	device	
being	used,	why	they	were	vaped,	how	vaping	changed	the	subjective	experience	and	pleasure	of	the	drug	and	
whether	or	not	vaping	became	the	dominant	route	of	use.	We	just	haven't	has	the	chance	to	analyse	the	data	yet	and	
to	be	honest	a	bit	like	the	medical	cannabis	section	we	need	funding	to	resource	the	additional	work	(	any	one	
interested	in	helping	us	just	e	mail	please).
GDS	has	highlighted	the	range	of	drugs	currently	being	vaped	using	new	technology	and	while	cannabis	preparations	
still	dominate	the	scene	– the	range	of	drugs	being	used	is	growing.	
Vaping	is	old	tech,	just	repackaged	and	remarketed	using	new	shiny	tech.	Many	heroin	users	already	vape	- (though	we	
incorrectly	term	it	smoking)	when	they	heat	heroin	on	a	foil	and	inhale	the	vapourised fumes.	Crack	users	vape	crack	in	
a	Martel	bottle.	
It’s	such	an	appealing	route	of	use.	But	any	route	that	supports	a	rapid	onset	of	action	through	rapid	rises	in	blood	
plasma	levels		carries	with	it	the	possibility	of	increased	rates	of	reinforcement	and	dependence.	
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Selected	data	presented	here	comes	from	the	section	that	includes
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Which of the following drugs have you ever tried to vape?
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Cocaine	– Global
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For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
Cocaine	remains	popular	as	the	stimulant	drug	of	choice	for	those	with	money.	Gram	for	gram	it	is	the	
most	expensive	commonly	used	drug	in	the	world.	However	it	varies	widely	in	price	across	the	world	from	
less	than	€10/gram	in	South	America,	€50/gram	in	parts	of	Europe	to	over	€250/gram	in	Australia.	In	many	
countries	there	is	also	a	well	established	two	tier	market	where	dealers	offer	a	better	quality	product	for	a	
premium	price.	Whether	you	get	what	you	pay	for	is	another	question.
This	year	GDS	is	focusing	on	how	the	growth	of	darknet markets	impact	on	how	people	use	cocaine.	While	
most	people	use	cocaine	on	an	infrequent	basis	(80%	use	<	10	times	per	year)	there	is	a	small	proportion	
of	people	whose	use	escalates	with	consumption	reaching	very	high	levels.	
Some	of	the	issues	limiting	use	among	the	masses	aside	from	price	will	be	access	and	the	variable	quality	
of	product.	The	darknet markets	offer	users	the	opportunity	to	obtain	good	quality	cocaine	with	reduced	
levels	of	perceived	risk.	As	such,	it	might	be	the	case	that	darknet markets	lead	to	more	harmful	use	by	
some	people.
Global Drug Survey GDS2017 © Not to be reproduced without authors permission
Background
Cocaine	use	patterns	and	adverse	experiences	
þMean	number	of	cocaine	use	days	in	the	last	year	by	gender	
þ The	%	who	had	used	1,	2-10,	11-50,	51-100,	101-200,	201-300	and	>	300	x	in	the	last	year	
þ How	much	cocaine	is	used	per	day
þ How	many	lines	users	get	from	one	gram	of	cocaine	
þ Howe	the	most	common	line	of	cocaine	in	your	country	looks	like
þ How	the	prices	for	cocaine	looks	like	and	where	users	buy	from
þ The	%	of	users	who	would	like	to	use	less	cocaine	and	preferred	styles	of	help	seeking
þ The	%	who	reported	having	sought	emergency	medical	treatment	in	the	last	12	months	as	a	result	of	
cocaine	use
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Selected	data	presented	here	comes	from	the	section	that	includes
A	total	of	22,081	cocaine	users	participated	in	GDS2017	and	were	used	in	the	preparation	of	the	this	report.
How	many	days	in	the	last	year	did	you	use	cocaine	All	vs.	Males	vs.	Females	
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53.0
22.6
3.8
2.2
Days	used	in	last	12	months	- all	(%)
1 2-10	 11-50	 51-100	 100+	
18.2
53.1
22.8
3.5
2.3
Days	used	in	last	12	months	– male	(%)
1 2-10	 11-50	 51-100	 100+	
18.9
52.5
21.9
4.6
2.0
Days	used	in	last	12	months	– female	(%)
1 2-10	 11-50	 51-100	 100+	
Mean	number	of	days	=	16 Mean	number	of	days	=	16 Mean	number	of	days	=	16
Global	cocaine	data
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Cocaine mean number of days used in	the last	year by country
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Where	did	you	buy	cocaine	on	the	last	occasion	you	purchased	it?	
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Use	over	the	previous	12	months
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Amount	used/day Frequency	of	use Worries	about	physical	health	 Worries	about	psychological	
health	
Level	of	control	over	use	
Gone	up	 Gone	down No	change	
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Changes in	own cocaine use over the last	12	months
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Cocaine	users	who	aim	to	use	less	cocaine	next	year	&	help	seeking	behavior
MDMA	&	Drug	Checking	- global
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For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
MDMA	remains	one	of	the	most	popular	illicit	drugs	in	the	world	and	is	mainly	used	recreationally	by	people	attending	
electronic	dance	music	events.	However,	the	methods	of	use	differ	cross-nationally	and	regionally.	The	use	of	MDMA	
crystals	and	powder	has	become	more	popular	in	recent	years	and	the	latest	rise	in	the	content	of	MDMA	in	ecstasy	
pills	in	Europe,	with	up	to	300mg	MDMA	per	pill,	has	influenced	the	consumption	habits	of	users	around	the	world.	
Most	importantly,	the	two	different	forms	are	often	combined	and	mixed	with	alcohol	and/or	other	drugs.	Thus,	
people	who	use	MDMA	usually	show	overall	risky	drug	use	patterns.	On	the	other	side,	new	study	findings	consider	
the	use	of	a	single	dose	of	MDMA	(75mg-125mg)	relatively	safe	and	MDMA	as	a	therapeutic	agent	is	gaining	significant	
traction	and	research	interest	worldwide.	
According	to	GDS2015	and	GDS2016,	less	than	1%	of	recent	MDMA	users	(0.9%	and	0.8%)	have	reported	seeking	
emergency	medical	treatment	(EMT)	in	the	previous	year	and	female	users	were	more	likely	to	report	adverse	health	
effects	following	the	use	of	MDMA.	In	GDS2017,	we	aimed	to	follow	up	on	MDMA	use	patterns,	EMT	reports	and,	for	
the	first	time,	also	about	whether	users	do	test	their	MDMA	before	using.
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Background
1)	More	enjoyable experience
2)	Better	value	for	money
3)	Less	risk	of	unwanted	effects
4)	Less severe comedown
5)	Less	risk	of	seeking	emergency	medical	treatment
6)	Less	development	of	tolerance	so	less	need	to	mix	drugs
7)	Less	vulnerable	to	environmental	risks
8)	Quicker	recovery
9)	Less impaired judgment
10)	Less	likely	to	be	a	burden	on	your	mates	and	ruin	their	night
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10	good reasons to use less MDMA	less often
þ The	average	number	of	days	of	MDMA	use	per	year
þ The	%	of	last	year	users	indicating	their	first	use	in	that	year
þ The	%	of	last	year	users	who	had	resumed	MDMA	after	a	break	in	the	year	before
þ The	%	of	last	year	users	who	use	from	more	than	one	batch	during	one	session
þ The	most	common	forms	of	MDMA	used	among	the	last	year	users
þ The	methods	to	define	the	MDMA	quality	and	quantity	before/after	consumption:	drug	checking
þ The	most	common	setting,	in	which	MDMA	is	consumed
þ The	usual	amount	of	use	for	both	MDMA	pills/	tablets	and	MDMA	crystal/	powder
þ The	%	of	last	year	users	who	would	like	to	reduce	their	MDMA	use	and	plans	to	seek	help
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Selected	data	presented	here	comes	from	the	section	that	includes
A	total	of	26,555	last	year	MDMA	users	participated	in	GDS2017	(=23.0%)	and	were	used	in	the	
preparation	of	the	this	section	of	the	GDS2017	report
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The	risk	of	both	short	and	longer	term	harms	are	related	to	the	
amount	used	per	session	and	the	frequency	of	use.	Most	people	
use	less	than	monthly	giving	the	body	enough	time	for	recovery	
which	reduces	risks	and	avoids	the	development	of	tolerance	
which	can	reduce	the	pleasure	that	people	get	from	taking	MDMA.
Average	number of days of ecstasy (MDMA)	use in	the last	12	months by country
*n=23,174	last	year users
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Main	method of MDMA	use =	swallow a	pill/	capsule containing MDMA	(see our blog
post – routes of use may matter	more than you think)
74.4% 73.7% 
70.1% 67.9% 
64.9% 62.6% 
59.3% 57.5% 
54.3% 53.9% 53.0% 52.8% 
49.8% 
48.9% 
47.4% 46.9% 45.8% 45.7% 44.4% 42.1% 42.1% 
37.3% 
34.6% 32.8% 30.9% 
18.9% 
13.3% 11.5% 
7.7% 
This	is	the	most	common	method	of	use	globally.
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Did you seek any information (content/purity)	on	the pill/powder you were using before using
MDMA	in	the last	12	months?	
Only one in	ten recent MDMA	users reported the direct or indirect
use of drug checking services to determine the content and	purity
of their drugs used.	The	low numbers are mainly due	to a	lack	of
drug checking services in	most countries	and	higher service use
prevalence among users can be found in	countries	where drug
checking is legally available,	such	as Switzerland and	Austria.
*n=>	16,500	last	year users
8.5% 
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Using	a	Drug	Checking	service Drug	Checking	service	used	by	a	friend Drug	Checking	service	used	by	the	dealer
Female	<25 Male	<25 All Female	25	+ Male	25	+ 
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What proportion of ecstasy pill users start by taking just	½	or ¼	of a	pill?
64.4% 
53.1% 
59.7% 
70.3% 
62.7% 
Female	<25 Male	<25 All Female	25	+ Male	25	+ 
Both	age	and	sex	seem	to	influence	risk	behavior	
related	to	the	use	of	ecstasy	pills.
‘Test	dosing	and	reducing	your	risk	of	exposure	to	high	dose	
all	at	once	reduce	your	risk	of	becoming	unwell.	Everyone	
should	start	with	a	half	or	a	quarter	– simple,	fun	and	fun’
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On	most	occasions	drug	related	harms	can	be	
more	closely	linked	to	individual	behaviour	than	
the	drug	its	self
Better	quality	drugs	are	only	safer	if	people	use	
them	more	sensibly
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The	%	of	MDMA	users	who	have	sought	EMT	in	the	last	12	months
2.2% 
1.1% 1.2% 1.2% 
0.7% 
Female	<25	(n=3,529) Male	<25	(n=8,734) All	(n=20,837) Female	25	+	(n=2,284) Male	25	+	(n=6,290) 
In	total,	250participants	reported seeking EMT	
following the use of MDMA.	Young	women were
significantly more likely to report having sought
emergency medical treatment following the use of
MDMA.
*n=	>20,000	last	year users
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4	year	trend	data	– global	EM&	seeking	by	last	year	MDMA	users	(combined	n	=	>90,000)
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þ The	%	of	last	year	ecstasy	users	who	start	with	¼	or	½	a	pill	when	using	from	a	new	batch
þ The	average	time	until	redose after	test	dose	of	a	pill
þ How	many	doses	you	get	from	1	gram	of	MDMA	powder
þ How	you	usually	measure	your	dose	when	using	MDMA	powder
þ The	%	of	last	year	MDMA	users	who	start	with	¼	or	½	when	using	from	a	new	batch
þ The	average	time	until	redose after	test	dose	of	MDMA	powder
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Key	results presented in	this section – MDMA	pills/	tablets vs.	powder/	crystal
þ The	%	of	MDMA	users	who	have	sought	EMT	in	the	last	12	months
þ The	form	and	the	amount	of	MDMA	pills/	powder	used	before	EMT
þ The	use	of	other	psychoactive	substances	and	the	duration	of	the	session
þ The	quality	of	the	MDMA	consumed	(retrospectively)	&	testing	efforts
þ Whether	people	test	dosed	their	drug	that	day
þ Whether	they	had	sued	any	drug	checking	service	that	day
þWere	they	drunk	when	they	started	using	MDMA
þ Mental	and	physical	well-being	before	EMT
þ Adverse	symptoms	before	EMT	and	hospital	admission
þ Impact	of	the	EMT	on	MDMA	and	other	drug	use
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Key	results presented in	this section – emergency medical treatment following use of
MDMA
A	total	of	26,555	last	year	MDMA	users	participated	in	GDS2017	and	were	used	in	the	
preparation	of	the	this	section	of	the	GDS2017	report
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MDMA	– what you do	when you take MDMA	matters (see our blog page)
Of	the	roughly	25,000	MDMA	users	from	around	the	world	who	took	part	in	GDS2017,	1.2%	sought	emergency	medical	treatment	(EMT)	in	the	previous	12	months.	Now	you	
could	argue	that	out	of	25,000	people	who	use	on	averaged	9	times	in	the	last	year	that	is	not	a	huge	figure,	working	out	at	1	episode	of	emergency	treatment	seeking	for	
every	1000	episodes	of	use.	And	I	do	agree	that	for	most	people	on	most	occasions,	MDMA	is	not	a	hugely	risky	drug	accepting	of	course	that	over	50	people	per	year	have	
died	from	MDMA	in	the	UK	for	last	3	years).		While	the	determinants	of	MDMA	risk	are	many	it	pretty	much	come	down	to	the	interaction	between	the	person,	the	amount	
and	types	of	drugs	they	take	and	what	they	do	when	they	use.		Among	the	most	important	things	are	dose,	overheating	and	under and	over	watering.	
The	finding	from	GDS2017	highlight	that	risks	vary	widely	across	cultures,	reflected	by	the	marked	variation	of	in	the	rates	of	MDMA	users	in	our	study	seeking	EMT	in	the	
last	year.	The	highest	rates	were	seen	in	Denmark	(2.5%)	and	lowest	rates	in	Italy	(0.3%).	Of	interest	was	the	relatively	high	rate	in	The	Netherlands	(1.7%)	and	the	falling	rate	
in	the	UK	(0.8%	down	from	1.2%	last	year).		The	downward	trend	in	the	UK	is	good	news	and	though	it	might	reflect	changes	in	sampling	or	how	people	decide	if	they	need	
to	seek	EMT,	I	like	to	think	it	might	be	down	to	people	in	the	UK	starting	to	use	more	safely	and	sensibly.	For	the	last	2	years GDS,	Mixmag,	The	Loop	and	lots	of	other	groups	
have	been	pushing	safer	use	of	MDMA	with	a	focus	on	how	to	manage	higher	dose	pills	and	high	purity	MDMA.	While	lots	of	the	advice	is	old	school	common	sense,	people	
sometimes	doubt	is	validity.	Some	of	the	findings	from	GDS2017	give	support	to	some	of	these	key	messages	and	that	what	you	do	or	don’t	do	on	the	night	makes	a	
difference.	
This	year	60%	of	MDMA	users	in	our	study	from	around	the	world	reported	taking	a	test	dose	from	new	batches	of	pills	or	powders	in	line	with	our	campaign	‘don’t	be	daft	
start	with	a	half’.		Lots	of	others	stayed	well	hydrated	and	avoided	too	much	booze.	The	time	between	first	and	second	doses	was on	average	75	minutes	– not	long	enough	
for	most	people	to	peak	and	avoid	peak	level	problems.	GDS	suggest	you	wait	2-3	hours	to	avoid	getting	too	intoxicated,	especially	after	your	first	dose.	But	overall,	most	
people,	most	of	the	time	seem	to	have	had	a	good	time	without	major	issues.	But	not	everyone.
So	who	were	the	1.2%	who	ended	up	seeking	EMT	and	what	had	they	done	that	day?	Over	half	had	used	pills	(55%),	30%	had	used	powder	and	15%	both.	Women	tended	to	
seek	treatment	2-3	times	more	frequently	than	men.		Only	one	in	5	took	a	test	dose	that	day,	over	half	were	already	drunk	before they	took	their	first	dose	of	MDMA,	40%	
took	more	than	usual	and	over	40%	reported	feeling	unwell	either	physically	or	psychological	unwell	before	they	started	using that	night.		Only	7%	reported	not	using	any	
other	drug	or	alcohol.	
fact	while	the	rest	of	the	world	has	seen	an	increase	in	the	
All	of	this	gives	really	gives	support	to	3	main	things	that	we	can	make	a	real	difference	– these	things	are	free,	easy	and	entirely	under	your	control.
Test	dose	from	new	batch	(start	of	using	a	small	amount	of	a	new	powder	or	a	¼	or	a	half	of	new	pill)	and	wait	at	least	2	hours	before	redosing	– 3	is	even	better.	
Don’t	get	drunk	before	you	start	dosing	(or	afterward	for	that	matter)	
If	you	don’t	feel	well	– don’t	take	anything,	save	it	for	another	day
1)	Choose your mates – spend more time	with mates who don‘t use pills/	go clubbing,	change your benchmark
2)	Start	your	night	later	and	end	it	earlier/	don’t	go	to	the	after	party	(Ok	sounds	a	bit	dull	but	makes	for	a	cheaper	
night)
3)	Don’t	mix	MDMA	with	other	drugs	– people	who	mix	with	other	drugs	end	up	using	more	
4)	Plan	your use – save	it for a	special occasion – MDMA	is not	ketchup!
5)	Don’t	take	out	more	than	you	need	or	plan	to	use	(some	people	find	it	hard	to	go	home	with	drugs	in	their	pocket)	
6)	Tell	your	mates	to	help	you/	support	you	– they	might	even	join	you!	
7)	Dose	differently	– spread	your	doses	out	– the	effects	last	longer	and	you	are	less	likely	to	take	too	much
8)	Plan	a	break	of a	few months and	remember people can have wicked nights out	without a	pill
9)	Think	about why you are using – if pills are being used to solve problems – find	another way
10)Think	about	what	else	you	might	be	doing	better	if	you	cut	back	– maybe	better	relationships/	work/	health?	
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10	ways to go about using less MDMA	this year if you want to use a	bit less
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We	hope	you	are	enjoying	this	report	
which	we	gladly	share	with	
you	with	for	free.	If	you	like	what	
Global	Drug	Survey	does
then	we’d	like	to	ask	
you	to	make	the	smallest	of	
donations	– the	price	of	joint,	a	pill,	a	line,	a	beer.	
Your	donation	will	help	us	carry	on	being	independent,	run	the	survey	and	
encourage	governments,	communities	and	people	to	have	honest	
conversations	about	drugs.	
Finding	this	interesting?	
Methamphetamine/amphetamine	
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
Selected	data	presented	here	comes	from	the	section	that	includes
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q Mean	number	of	days	people	who	used	methamphetamine	reported	using	in	the	last	year	(broken	down	
by	gender)	and	the	%	using	more	than	10	times,	50	times	and	100	times	in	the	last	12	months
q How	much	methamphetamine	do	you	usually	use	on	a	day	of	use
q Global	comparison	of	mean	amount	used	/	day
q How	do	you	most	commonly	take	methamphetamine
q How	much	does	it	cost	to	purchase	a	single	gram	of	methamphetamine	
q Approximately	how	many	times	did	you	buy	methamphetamine	in	last	12	months	
q Who	did	you	buy	it	from	the	last	time	you	bought	it?
q The	%	who	would	like	to	use	less	methamphetamine	(powder/base	combined)	over	the	next	12	months
q Of	those	who	want	to	use	less,	the	%	that	would	like	help	to	use	less
q The	%	seeking	EMT	in	the	last	12	months		(split	by	age	and	gender)	
A	total	of	6000	last	year	amphetamine	/	methamphetamine	users	participated	in	GDS2017	and	were	used	
in	the	preparation	of	this	section	of	the	report
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How	do	you	most	commonly	use	amphetamine	v	base	v	methamphetamine
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Seeking	emergency	medical	treatment	following	the	use	of	methamphetamine	
powder/base	in	the	last	12	months	(M	v	F)	only	for	countries	with	n	>	100	last	year	users
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LSD	and	Magic	Mushrooms	Part	1
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
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Background
MMs	and	magic	mushrooms	remain	the	world’s	most	commonly	used	psychedelic	drugs.	With	both	drugs	enjoying	a	
renaissance	with	their	long	held	therapeutic	potential	question	and	use	by	individuals	to	enhance	self	awareness	and	well-
being.	
This	year	GDS	is	focusing	on	people’s	psychedelic	careers	exploring	how	old	they	were	when	they	first	used	and	where	they	
were	and	how	their	patterns	of	use	may	have	changed	over	the	years.	We	will	report	on	the	the	different	functions	that	these	
drugs	may	have	been	used	for	before	focusing	on	current	patterns	and	preparations	of	use	and	whether	or	not	people	
reported	needing	to	seek	emergency	medical	treatment	each	year.	
We	also	report	on	the	use	of	psychedelics	for	performance	enhancement	(so	called	micro-dosing)	and	spiritual	enlightenment	
(in	partnership	with	shamans	or	therapists)	as	well	as	defining	what	makes	a	bad	trip	and	how	people	manage	these	
challenging	experiences.	
LSD
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
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Over	25,	000	last	year	users	of	LSD	and	magic	mushrooms	were	used	in	the	production	of	the	
global	findings	for	this	section	of	the	report		
Selected	data	presented	here	comes	from	the	section	that	includes:
COUNTRY	SPECIFIC	DATA	ON	RECENT	USE
• How	old	were	you	when	you	first	used	LSD
• Mean	number	of	days	people	had	used	LSD	in	their	lifetime	and	%	in	the	last	12	months
• Where	were	they	when	they	first	used	LSD	and	in	what	environment?
• What	is	the	most	common	preparation	pf	LSD	people	had	used?
• How	many	doses	would	you	take	on	a	day	– modal	value	and	%	reporting	used	3	or	more	doses	in	a	day	
GLOBAL	FINDINGS	ON	
• Price	per	tab	(in	EUROS)	
• %	needing	to	go	hospital	for	emergency	medical	treatment	M	v	F
• Reasons	why	they	thought	they	ended	up	needing	help	
GDS2	4	Year	UK	trends	in	psychedelic	use	 (n	=	25,000	across	the	4	years)
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Where,	and	age	of	first	use	of	LSD	(global	sample)
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Seeking	emergency	medical	treatment	following	the	use	of	LSD	in	the	last	12	
months	(GLOBAL)		
Out	of	almost	10,000	last	year	LSD	consumers	who	took	part	in	GDS2017	1%	(n	=	95,	78	men	
and	17	women)	reported	seeking	emergency	medical	treatment.	
There	was	no	significant	different	in	rates	between	male	and	females.
The	rate	is	considerably	higher	(5	times	greater)	than	with	magic	mushrooms	presumably	
because	of	the	greater	difficulties	in	dosing	accurately	with	LSD	tabs	whose	content	may	vary	
from	25	micrograms	to	over	300	micrograms		and	because	of	the	longer	action	of	LSD	v	
psilocybin	(the	active	ingredient	in	magic	mushrooms)	.	People	who	use	psychedelics	are	
generally	very	sensible	and	show	some	of	the	best	preparation	and	adoption	of	harm	reduction	
practices	of	any	drug	(see	the	Global	Drug	Survey	highway	
https://www.globaldrugsurvey.com/wp-content/uploads/2014/04/The-High-Way-
Code_LSD.pdf
Magic	mushrooms
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
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Selected	data	presented	here	comes	from	the	section	that	includes:
COUNTRY	SPECIFIC	DATA	ON	RECENT	USE
• How	old	were	you	when	you	first	used	Magic	Mushrooms	(MMs)
• Mean	number	of	days	people	had	used	MMs	in	their	lifetime	and	%	in	the	last	12	months
• Where	were	they	when	they	first	used	MMs	and	in	what	environment?
• What	is	the	most	common	form	of	MMs	you	have	used	MMs	?
• How	many	doses	would	you	take	on	a	day	– modal	value	and	%	reporting	used	3	or	more	doses	in	a	day	
GLOBAL	FINDINGS	ON	
• Number	of	mushrooms	taken	in		session
• %	needing	to	go	hospital	for	emergency	medical	treatment	M	v	F
Which	countries	are	most	likely	to	pick	their	own	/	grow	their	own	magic	mushrooms	
(only	countries	with	n	>	100	last	year	users)
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Seeking	emergency	medical	treatment	following	the	use	of	MMs	in	the	last	12	
months	
Out	of	almost	10,000	last	year	magic	mushroom	consumers	only	0.2%	(n	=	17,	13	men	and	4	
women)	reported	seeking	emergency	medical	treatment.	Magic	mushrooms	were	the	safest	
drugs	to	take	in	terms	of	needing	to	see	emergency	medical	treatment	according	to	GDS2017
There	was	no	significant	different	in	rates	between	male	and	females.
The	rate	is	considerably	lower	than	with	LSD	presumably	because	of	intrinsic	safety	of	magic	
mushrooms	(	the	greatest	risk	is	picking	the	wrong	type),	the	smaller	dosing	using	units	(a	
single	mushroom	v	an	LSD	tab)	and	greater	understanding	of	how	many	mushrooms	may	
constitute	a typical	dose	for	a	desired	effect	in	your	region.	People	who	use	psychedelics	are	
generally	very	sensible	and	show	some	of	the	best	preparation	and	adoption	of	harm	
reduction	practices	of	any	drug	(see	the	Global	Drug	Survey	highway	
https://www.globaldrugsurvey.com/wp-content/uploads/2014/04/The-High-Way-
Code_LSD.pdf
Psychedelics	Specialist	Section
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
Difficult	/	negative	experiences	
þ The	%	of	ever-users	reporting	having	had	a	difficult/negative	experience	while	under	the	influence	of	psychedelics	
þ The	%	of	recent	users	(12m)	reporting	having	had	a	difficult/negative	experience	in	the	last	12	months	
þ The	experiences	that	were	most	commonly	considered	as	difficult	or	challenging	(by	gender)
þ The	%	who	describe	their	most	recent	difficult/negative	experience	as	a	bad	trip	(yes,	no,	unsure)	
þ The	most	common	approaches	adopted	by	people	to	manage	this	most	recent	difficult/negative	experience	
Micro-dosing	and	performance	enhancement	
þ The	%	reporting	micro-dosing	with	LSD/	other	psychedelics	in	the	last	12	months	
þ The	common	patterns	of	micro-dosing	and	perceived	benefits
þ The	impact	of	micro-dosing	on	other	medications/	therapies	used	by	the	individual	
Ceremonial	use	of	psychedelics	with	shamans/	healers
þ The	%	of	ever-users	reporting	having	taken	psychedelics	at	least	once	under	the	supervision	of	a	shaman/	healer
þ The	%	of users who have already travelled to another country for such	a	„retreat“.
þ Rating	of the ritual	use and	shamans‘	check	for current mental/	physical health issues before ritual.
Who	do	people	tell	about	their	use	of	psychedelics	and	why	do	people	use	them?
þ The	main	motivations	for	psychedelic	use	over	a	lifetime
þ Fears	and	responses	over	disclosing	use	to	close	family
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Selected	data	presented	here	comes	from	the	section	that	includes:
A	total	of	5,600	ever-users	participated	in	GDS2017	specialist	section	on	
psychedelics	and	were	used	in	the	preparation	of	this	reports	section.
Have	you	have	ever	had	a	difficult/negative	experience	while	under	the	influence	of	LSD	or	any	other	
psychedelic?	
• The	%	of	ever	users of	LSD,	psilocybin,	2C-drugs,	NBOMe,	smoked	DMT,	Ayahuasca and/or	Peyote	who	
reported	having	ever	had	a	difficult/negative	experience	
• The	%	of	last	12	month	users	of	LSD,	psilocybin,	2C-drugs,	NBOMe,	smoked	DMT,	Ayahuasca and/or	Peyote	
who	reported	having	had	a	difficult/negative	experience	in	the	last	12	months	
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Difficult/	negative	experiences	while	under	the	influence	of	psychedelics	(global)
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• Check	out	our	excellent	blog	
Understanding	and	Working	with	
Difficult	Psychedelic	Experiences	by	D	
Sara	Gael	from	MAPS	
https://www.globaldrugsurvey.com/gds2
017-launch/understanding-and-working-
with-difficult-psychedelic-experiences/
• And	see	our	video	on	safer	dosing	and	using	
with	mushrooms	on	our	YouTube	Chanel	
https://youtu.be/6fxdhU9HCFc
Check	out	the	GDS	Highway	Code	
https://www.globaldrugsurvey.com/brand/t
he-highway-code/
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Keeping	you	and	your	mates	safe	when	you	use	psychedelics	– advice	from	GDS	
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Psychedelics	truly	are	experiencing	somewhat	of	a	renaissance	after	being	flatly	ignored	and	outright	banned	from	
human	scientific	research	for	many	decades.	One	area	that	is	still	in	its	infancy	is	the	practice	of	using	very	small	doses	of	
psychedelics	to	improve	mood	and	cognitive	performance.	At	first,	it	may	not	be	immediately	obvious	how	a	drug	that	
can	make	you	see	fractal	spirals	in	your	lunch	box	could	possibly	improve	your	work	performance.	But	it	might	be	that	by	
opening	connections	between	parts	of	your	brain	that	don’t	usually	communicate	(not	since	childhood	at	least)	these	
sparking	drugs	can	help	our	brains	perform	outside	of	the	box.	In	this	section,	we	report	on	just	how	common	this	
practice	is,	how	useful	it	is	perceived	to	be	and	for	those	who	look	to	treat	medical	conditions	what	the	impact	on	pre-
existing	therapies	has	been.	
As	a	starter,	we’ll	share	a	finding	from	the	GDS	mini	survey	in	2016,	which	was	answered	by	12,300	people.	In	that	
sample,	6.2%	(n=755)	reported	having	micro-dosed	with	LSD	(10-30mcg)	at	least	once.	Two thirds (64.3%)	mentioned
that their dosing was	guess work – that is trial and	error using farctions of LSD	tabs bought from a	dealer or on	darknet
markets.	Please note that the psychedelics part of the GDS	mini	survey was	announced in	the newspaper and	that this is
not	a	prevalence estimates,	but	rather a	description of the sample	reached.
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Micro-dosing
Darknet markets	or	cryptomarkets
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
Darknet markets	or	cryptomarkets have	now	been	operating	for	6	years	(since	the	launch	of	Silk	Road	in	
February	2011).	In	the	dark	or	hidden	web,	site	owners,	vendors	and	buyers	are	able	to	remain	relatively	
anonymous	as	their	IP	addresses	are	masked.	Purchases	are	made	using	the	decentralised	virtual	currency	
Bitcoin,	which	can	also	be	used	relatively	anonymously.	
Three	years	after	the	demise	of	Silk	Road,	there	is	still	volatility	in	the	cryptomarket ecosystem:	exit	scams,	
where	market	owners	close	the	market	unexpectedly	and	steal	the	funds,	have	become	commonplace.	
Despite	disruptions	from	law	enforcement	efforts	and	scams,	the	size	and	scale	of	darknet markets	for	drugs	
continues	to	grow.	At	the	time	of	survey	there	were	over	20	functioning	markets	according	to	dnstats.net.	
GDS	conducted	the	first	survey	about	users	of	cryptomarkets in	2012	and	has	remained	at	the	forefront	of	
survey	work	in	this	area,	sampling	cryptomarket users	on	an	annual	basis.	
The	sample	used	in	this	report	includes	63,212 respondents	who	completed	the	darknet market	section	this	
year,	all	of	whom	reported	last-year	use	of	drugs	(including	pharmaceutical	and	novel	substances).	
Background	
Selected	data	presented	here	comes	from	the	section	that	includes
From	the	darknet market	section	in	the	GDS
þ Have	you	obtained	drugs	from	darknet markets	in	the	last	12	months?	(includes	personal	purchase,	arranged	by	
others,	and	purchased	on	behalf	of	others	or	with	intent	to	supply	to	others)	- by	country;	4-yr	trends
þ How	many	times	and	through	how	many	different	markets	have	you	obtained	drugs?	– global	3-yr	trends
þ Which	drug	types	and	how	many	different	types	have	you	obtained	from	darknet markets?	– global	3-yr	trends
þ What	proportion	of	these	drugs	purchased	through	darknet vendors	in	your	own	country	or	from	abroad?	– global	
2017	and	by	country
þ How	has	accessing	drugs	through	darknet markets	affected	the	range	of	(any)	drugs	you	have	consumed?	– global	3-yr	
trends
þ Regarding	the	most	recent	darknet market	purchase,	why	did	you	choose	this	vendor?	Did	you	use	encryption?	Did	
you	finalise	early	(pay	before	receiving)?	– global	2017
þ Demographics	of	last-year	darknet market	users	vs.	other	last-year	drug	users	who	did	not	use	darknet – by	country	
2017
GDS2017:	The	total	N	is	63,212	used	for	the	analysis	of	this	version	of	the	report.	The	total	N	ever	obtained	drugs	
from	darknet markets	is	6,935.	
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2017:	Have	you	obtained	drugs	from	darknet markets	in	the	last	12	months?	(%)
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Country Total	N
Germany 20,298
United	States 5,655
Denmark 5,444
Switzerland 3,720
Australia 3,414
Canada 3,155
United	Kingdom 3,118
Austria 2,913
New	Zealand 2,316
Italy 1,963
Netherlands 1,433
Hungary 1,369
Brazil 1,340
Mexico 638
Greece 622
Colombia 539
Portugal 488
Belgium 444
Scotland 414
Norway 342
Sweden 282
France 273
Spain 257
Poland 253
Finland 244
Ireland 227
Iceland 143
Wales 132
Argentina 120
Croatia 119Base	sample:	Last year	use	of	 illicit	drugs,	new	psychoactive	substances	and/or	prescription	drugs*	Includes	those	who	report	personally purchasing	drugs,	arranging	for	others	to	purchase	drugs	or	purchasing	on	behalf	of	others	from	darknet	markets.
Global Drug Survey GDS2017 © Not to be reproduced without authors permission
4-yr	trends:	obtained	drugs	from	darknet markets	in	the	last	12	months	(%)
English-speaking	countries
Base	sample:	Last year	use	of	 illicit	drugs,	new	psychoactive	substances	and/or	prescription	drugs
*	Includes	those	who	report	personally purchasing	drugs,	arranging	for	others	to	purchase	drugs	or	purchasing	on	behalf	of	others	from	darknet	markets.
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3-yr	trends:	which	drug	types	have	you	(ever)	obtained	through	darknet markets?	(%)
Base	sample:	Ever personally purchased	drugs,	arranged	for	others	to	purchase	drugs	or	purchased	on	behalf	of	others	from	darknet	markets.
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Example	data	for	‘a	country’	.	Demographics	of	last-year	darknet	users	(n=XXX	)	&	drug	types	obtained
Demographics	of	last-year	darknet	users	were	
*:
• Younger:	median	age	24	vs	40	yrs
• More	likely	to	be	male:	87%	vs	67%
• Less	likely	to	report	completion	of	a	
university	degree:	41%	vs	51%
• Similar	likelihood	of	paid	employment:	77%	
vs	74%
• More	likely	to	report	living	in	a	city/urban	
area:	87%	vs	76%
• More	likely	to	report	going	clubbing	
monthly+:	29%	vs	11%
In	a	logistic	regression,	younger	age,	being	
male,	and	clubbing	monthly	or	more	often	
were	associated	with	last-year	darknet use.
*	Compared	with	‘a	country’	last-year	use	of illicit	drugs,	new	psychoactive	substances	and/or	prescription	drugs	who	DID NOT	report	last-year	darknet	use.
Drug	types	ever	obtained	through	darknet markets	%
40%	report	only	ever	obtaining	1	drug	type	(rest	of	sample	46%)
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For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
BACKGROUND TO NPS
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Background
• GDS has been tracking the use of ‘Novel Psychoactive Substances’ legal highs’, ‘research chemicals’ for the last 5 
years.
• While there may be many new substances identified each week just because drugs are available on line or in ‘head 
shops’ it does mean they are being used. 
• Overall there was increase in the percentage of Global GDS respondents  who reported purchasing NPS in the last 
12 months from 4.2% to 4.8%, with many countries seeing a notable increase in use. 
• GDS thinks where people have good access to good quality traditional drugs the interest in NPS is generally low 
(for example in Switzerland). The Desert Island Drugs section and motivations for use will expand on this 
hypothesis
• The reduction in last year use in countries such as New Zealand suggests closing ‘head shops’ might lead to 
reduced sales a point that is of importance given that there appears to have been an increase in the proportion of 
GDS respondents globally of people buying from shops – though this show marked regional variation. 
• There also seems to have been increase in the use of pills and powders compared to smoking mixtures though 
again there are marked regional variations. 
Background
GDS	has	been	tracking	the	use	of	‘Novel	Psychoactive	Substances’,	‘legal	highs’	and	‘research	chemicals’	for	the	last	6	
years.	The	use	of	different	NPS	show	marked	regional	variation	and	often	reflect	the	availability,	regulation	and	price	
of	traditional	drugs	within	a	region.	For	example	the	Netherlands	show	one	of	the	lowest	rates	of	synthetic	
cannabinoid	receptor	agonist	(SCRA)	use	in	the	world	reflecting	easy	and	regulated	access	to	natural	cannabis.	
Conversely	despite	ready	availability	of	other	traditi n l	drugs	they	report	one	of	highest	rates	of	 PS	use	among	the	
GDS	sa ple.	
NPS	va y	widely	i 	the r	risk	profile,	with	inconsistent	compositio 	and	potency	often	being	significa 	factors	in	the	
risks	they	pose.	Highly	potent	hallucinogen	compounds	like	NBOMe,	and	potent	amphetamine	analogues	like	4-Flour-
Amphetamine	are	causing	real	co cern	across	Europe	and	Australia	where	their	use	has	been	associated	with	deaths	
in	recent	months.	GDS2017	suggests	drugs	with	a	psychedelic	effect	profile	(including	LSD	analogues)	are	on	the	
increase	with	these	drugs	representing	over	50%	of	the	NPS	drugs	being	used	by	the	sample.	Potent	novel	opioid	
drugs	like	acetyl	fentany and	carfentanyl have	been	responsible	for	scores	of	deaths	in	Canada	and	these	are	ones	to	
watch	in	future	years.
Overall	there	seems	to	have	been	a	shift	away	from	herbal	smoking	mixtures	with	an	increase	in	powders	and	liquids.	
The	impact	of	regional	variations	in	drug	laws	and	tolerance	for	drug	use	can	also	be	seen	in	the	findings	this	year.
Selected	data	presented	here	comes	from	the	section	that	includes:
þGlobal	comparison	of	GDS	countries	– NPS	use	in	the	past	12	months
þGlobal	comparison	of	GDS	countries	– NPS	purchase	in	the	past	12	months
þWho	in	your	country	had	bought	NPS	in	the	past	12	months	(gender,	age	and	clubbing)
þComparison	of	NPS	types	(preparations)	used	over	the	last	3	years	using	the	global	GDS2017	
sample	of	last	year	NPS	users
þWhat	preparations	of	NPS	were	most	commonly	used	in	your	country	in	the	last	12	months?	
þGlobal	overview	of	types	of	drug	effect	NPS	preparations	used	in	the	past	12	months	are	trying	to	
mimic	V	those	in	your	country
þSource	of	purchase	of	NPS	in	the	past	12	months	global	GDS2017	v	your	country.	
þThe	%	of	all	participants	who	recently	used	NPS	and	sought	EMT	in	past	12	months
A	total	of	9000	last	year	users	of	NPS	from	the	full	GDS2017	sample	were	used	in	the	preparation	of	
the	global	findings	section	of	the	report.	
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NPS	purchase in	the	past	12	months	by	country
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What	was	the	appearance	/	form	of	the	NPS	used	(using	global	GDS	samples	over	
last	3	years)	?
What	drug	effects	are	NPS	trying	to	mimic	most	often	(GDS2017	GLOBAL)?	
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We	hope	you	are	enjoying	this	report	
which	we	gladly	share	with	
you	with	for	free.	If	you	like	what	
Global	Drug	Survey	does
then	we’d	like	to	ask	
you	to	make	the	smallest	of	
donations	– the	price	of	joint,	a	pill,	a	line,	a	beer.	
Your	donation	will	help	us	carry	on	being	independent,	run	the	survey	and	
encourage	governments,	communities	and	people	to	have	honest	
conversations	about	drugs.	
Finding	this	interesting?	
Seeking	Emergency	Medical	
Treatment	after	drug	use
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For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
Why	look	at	rates	of	seeking	emergency	medical	treatment	?	
• Seeking	emergency	medical	treatment	can	be	taken	as	a	proxy	measure	for	the	acute	
harms	experienced	following	the	use	of	alcohol	and	other	drugs
• Emergency	medical	attendance	and	admission	also	represent	significant	economic	
burden	upon	acute	medical	services
• While	the	press	often	highlights	attendance	at	A+E	departments	as	a	frequent	
occurrence	among	those	who	drink	and	take	drugs	there	is	little	date	on	the	actual	
prevalence	of	such	treatment	seeking	among	people	in	the	general	population
• This	year	we	asked	last	year	users	of	the	most	commonly	taken	substances	whether	
they	had	sought	emergency	medical	treatment
What	this	section	covers
• Whether	participants	had	needed	to	seek	emergency	medical	treatment	in	the	last	
12	months	as	a	result	of	using	a	number	of	drugs
• This	section	compares	the	percentages	of	those	last	year	users	of	different	drugs	
using	the	entire	GDS2017	sample.	
• This	is	the	first	time	we	have	include	rates	for	methamphetamine	– which	carries	
the	greatest	risk	for	seeking	EMT,	even	more	than	the	synthetic	cannabinoid	drugs	
which	have	been	this	category's	winner	for	the	last	4	years.		
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GDS	advice	on	taking	a	new	drug	for	the	first	time
The	biggest	risk	is	starting	off	taking	lots	of	an	unknown	
drug	before	you	know	how	long	it	takes	to	come	on,	peak	
and	starting	coming	down	– so	easy	does	it.	Test	drive	it	
before	putting	your	foot	down.	
•Wait	for	at	least	90-120	minutes	before	re-dosing
•Choose	your	time	– don’t	be	coming	down	or	experiment	
on	the	back	of	a	bender
•Don’t	have	anything	else	on	board/including	prescribed	
medications
•Don’t	be	on	your	own	
•Plan	ahead	before	you’re	too	off	your	head
•Make	sure	others	know	what	you	have	taken	and	that	at	
least	one	of	them	is	not	intoxicated
•If	you	feel	unwell	let	someone	you	know	and	seek	help
•Be	in	a	safe	place	– familiar
•First	dose	should	be	at	least	a	quarter	of	what	you	think	a	
tiny	dose	is	(or	a	maximum	quarter	of	a	pill)
•Avoid	taking	other	drugs/alcohol	after	dosing	
•Don’t	drive/bath/play	with	knives
•Accept	many	drugs	wont	be	very	good/effective	or	nice
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Comparison	by	drug	:	Seeking	Emergency	Medical	Treatment	(EMT)	by	last	year	users	
(global	sample)	
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Note	the	higher	rates	of	seeking	EMT	for	women	than	
men	for	many	substances		 Magic	mushrooms	seem	to	
carry	the	lowest	acute	risk	
of	harm	of	any	drug
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GDS	3	year	trends	in	people	seeking	EMT	after	commonly	used	substances	(	>	300,000)
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Note	the	increases	for	MDMA	and	cocaine	and	the	fall	for	cannabis.
Policing
For	more	data	including	country	based	reports	please	e-mail	
info@globaldrugsurvey.com to	discuss	costing	and	analyses	required.	
Getting	caught	with	drugs	can	be	a	very	stressful	event	in	people’s	lives.	Criminal	records	for	personal	
possession	of	drugs	can	ruin	careers	and	opportunities	and	costs	the	police	and	legal	system	considerable	time	
and	money	for	uncertain	gain.	Encounters	with	newer	policing	methods	of	drug	detection	dogs	(“sniffer	dogs”)	
can	encourage	high	risk	behaviours	e.g.	people	consuming	all	their	drugs,	to	avoid	being	caught	in	their	
possession.	While	we	know	a	lot	about	how	different	drug	laws	operate	across	the	globe	– we	know	very	little	
about	how	often	people	who	use	drugs	are	stopped	by	police	and	the	similarities	and	differences	in	policing	
experiences	across	the	globe.
So	this	year	the	GDS2017	included	a	specific	policing	module,	that	will	provide	the	first	insights	into	drug-
related	policing	encounters	across	the	globe.	
A	total	of	50,000	respondents	to	GDS2017	completed	the	policing	section,	all	of	whom	reported	using	drugs	in	
the	last	12	months.	All	were	used	in	the	preparation	of	this	report.
This	section	should	be	read	in	conjunction	with	the	accompanying		blog	written	by	Adam	Winstock	and	Caitlin	
Hughes	‘How	do	police	deal	with	drug	possession	around	the	world?	New	insights	from	the	GDS2017’.	
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Background	
Key	results	presented	in	this	section
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From	the	drugs	policing	section	in	the	GDS2017	
þ How	many	recent	drug	users	have	been	stopped	by	police	in	relation	to	their	drug	use	or	other	drug-related	behaviour
in	the	last	12	months?	
þ Who	is	most	and	least	likely	to	be	picked	up?	e.g.	males	versus	females?
þ How	much	do	experiences	of	drugs	policing	vary	across	globe?	
þ Of	note	we	show	here:	
þ Which	countries	have	the	highest	level	of	drug-related	police	encounters?	
þ Which	countries	most	use	drug		detection	dogs	or	“sniffer	dogs”?
þ Which	countries	have	the	highest	rate	of	police	bribes	for	drugs?
A	total	of	49,869	respondents	to	GDS2017	completed	the	policing	section	and	
were	used	in	the	preparation	of	this	report
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Some	types	of	policing	appear	more	common	in	some	parts	of	the	globe.	Of	note,	
encounters	with	police	drug	detection	dogs	(“sniffer	dogs”)	were	higher	in	three	nations
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We	hope	you	enjoyed	this	report	
which	we	gladly	share	with	
you	with	for	free.	If	you	like	what	
Global	Drug	Survey	does
then	we’d	like	to	ask	
you	to	make	the	smallest	of	
donations	– the	price	of	joint,	a	pill,	a	line,	a	beer.	
Your	donation	will	help	us	carry	on	being	independent,	run	the	survey	and	
encourage	governments,	communities	and	people	to	have	honest	
conversations	about	drugs.	
Was	this	interesting?	
If	you	would	like	to	get	your	country	or	region	involved	in	GDS2018	
please	e	mail	us	at	info@globaldrugsurvey.com
